• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Precision Ocular raises $19m, inks deal with Consort Medical for drug-device combo

February 22, 2016 By Fink Densford

Consort Medical, Precision OcularConsort Medical said today it inked a development and manufacturing deal with Precision Ocular, and joined in a round of financing to support Precision Ocular, who raised $19 million (UK £13.5 million) total.

The collaborative deal will leverage Consort subsidiaries Bespak and Aesica, with Bespak providing device development and manufacturing capabilities and Aesica offering manufacturing and filling, according to a press release.

“This is an exciting new partnership which will draw on the skills and expertise of both Consort companies, Bespak and Aesica, and is an important demonstration of the value of our recently announced single solution for device and drug combinations.  Further it extends our competencies into the ocular therapeutic area in line with our stated strategy. Consort Medical is at the leading edge of innovation and our participation in Precision Ocular’s equity financing once again highlights our commitment to investing in companies that are at the forefront of the development of new treatments, new markets and new opportunities,” Consort Medical CEO Jon Glenn said in prepared remarks.

Consort Medical said the deal will focus on the development, scaling up and industrialization of Precision Ocular’s novel drugs and drug delivery system, designed to access small spaces in the eye to provide drug distribution to tissues involved in retinal diseases.

“We are pleased to have Bespak as our development and manufacturing partner: this collaboration marks an important step in the commercial development of Precision Ocular.  A significant attraction for us is Consort Medical’s ability to offer Precision Ocular a one stop shop for development and eventual commercial manufacture of the final filled, finished and packaged product,” Precision Ocular CEO Tom Cavanagh said in a prepared statement.

In its $19 million round of financing, Precision Ocular received $4.7 million (UK £3.3 million) from Consort Medical, with a 1st tranche of $2.8 million (UK £2 million). Consort Medical said it will also have a position on Precision Ocular’s board.

Also joining the round were Imperial Innovations, Hovione and NeoMed, according to a press release from Consort Medical.

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Consort Medical, Precision Ocular

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS